GLP-3 RTA+ Cagrilintide 15mg Blend Bali

Rp3,700,000.00 ~$224.24

Discover the Atlas Longevity GLP-3 RTA + Cagrilintide Blend 15mg, an experimental research formulation combining two compounds investigated for appetite regulation, body-weight management and metabolic signalling.

Each vial contains:

  • GLP-3 RTA : 10mg
  • Cagrilintide: 5mg
  • Total labelled content: 15mg
  • Ratio: 2:1 by mass
  • Format: Research peptide vial
  • Research Area: Metabolic health and appetite regulation

GLP-3 RTA targets GLP-1, GIP and glucagon receptors, while cagrilintide is a long-acting amylin analogue.

For laboratory research only. Not approved for human consumption or self-administration.

Your vial includes 3ml Bac Water + 6 Syringes + 6 Alcohol Pads.
20%
WELCOME OFFER Get 20% Off Your Order

Use code WELCOME20 at checkout. Valid for the first 100 orders only.

Available on backorder

Description

GLP-3 RTA + Cagrilintide Blend 15mg Bali

Reta Cag Dual-Peptide Research Blend

The GLP-3 RTA 10mg + Cagrilintide 5mg Blend combines two investigational peptides in a single vial.

GLP-3 RTA is a triple receptor agonist studied in clinical trials involving obesity and metabolic health.

Cagrilintide is a long-acting amylin analogue investigated for appetite regulation, satiety and weight-management outcomes.

Although the compounds have been investigated individually, this specific combined formulation has not been established as safe or effective in human clinical trials.

 

What’s Inside the 15mg Blend?

Ingredient Quantity Research Focus
GLP-3 RTA 10mg GLP-1, GIP and glucagon receptor signalling
Cagrilintide 5mg Amylin receptor signalling and satiety research
Total 15mg Experimental metabolic peptide blend

What Is GLP-3 RTA?

GLP-3 RTA is an investigational peptide that activates three hormone receptors:

  • GLP-1: Associated with appetite and glucose regulation
  • GIP: Involved in glucose-dependent metabolic signalling
  • Glucagon: Involved in hepatic metabolism and energy regulation

GLP-3 RTA has been studied in clinical trials for obesity and related metabolic conditions.

What Is Cagrilintide?

Cagrilintide is an investigational long-acting amylin analogue.

Amylin is a hormone involved in appetite regulation, satiety and gastric emptying.

Cagrilintide has been investigated in clinical research involving body-weight management, including studies combining it with semaglutide.

GLP-3 RTA + Cagrilintide Research Areas

The individual ingredients have been studied in relation to:

  • Appetite regulation
  • Satiety signalling
  • Body-weight management
  • Glucose metabolism
  • Obesity-related metabolic pathways
  • Incretin and amylin receptor activity

These research areas do not demonstrate that combining GLP-3 RTA and cagrilintide in one vial produces additional benefits.

GLP-3 RTA + Cagrilintide vs Other Peptides

Compound Primary Mechanism
GLP-3 RTA GLP-1 + GIP + Glucagon receptor agonist
Cagrilintide Long-acting amylin analogue
Semaglutide GLP-1 receptor agonist
Tirzepatide GLP-1 + GIP receptor agonist
GLP-3 RTA + Cagrilintide Experimental combination of triple agonist and amylin analogue

The compounds differ in clinical evidence, regulatory status and safety profile. They are not interchangeable.

Product Specifications

Product: GLP-3 RTA + Cagrilintide Blend

Brand: Atlas Longevity

GLP-3 RTA Content: 10mg

Cagrilintide Content: 5mg

Total Labelled Content: 15mg

Ingredient Ratio: 2:1 by mass

Format: Research peptide vial

Category: Fat Loss & Metabolic Health

Classification: Investigational peptide combination

Intended Use: Laboratory research only

Quality & Batch Documentation

Contact Atlas Longevity to request available batch-specific analytical documentation.

For combination products, testing should assess the identity and quantity of each ingredient wherever validated methods permit.

A Certificate of Analysis does not, by itself, demonstrate sterility, clinical safety or pharmaceutical approval.

Storage

Follow the verified storage instructions supplied for the specific formulation and batch.

Protect from excessive heat, direct sunlight and contamination.

The stability and compatibility of GLP-3 RTA and cagrilintide when combined in one vial should not be assumed without formulation-specific testing.

Safety Information

GLP-3 RTA and cagrilintide are pharmacologically active investigational compounds.

Clinical studies of the individual compounds have reported gastrointestinal adverse effects such as nausea, vomiting and diarrhoea.

The safety, interactions and adverse-effect profile of this specific 15mg blend have not been established.

Atlas Longevity Bali

Atlas Longevity provides information about research peptides and metabolic health compounds.

Contact our team for batch documentation, product specifications and regulatory information.

Any supply must comply with applicable Indonesian regulations.


Frequently Asked Questions

What is GLP-3 RTAv + Cagrilintide Blend?

It is an experimental combination of GLP-3 RTA, a triple receptor agonist, and cagrilintide, a long-acting amylin analogue.

How much peptide is in each vial?

Each vial is labelled as containing 15mg total: 10mg GLP-3 RTA and 5mg cagrilintide.

What is Reta Cag Blend?

Reta Cag is a shortened name sometimes used to describe a GLP-3 RTA and cagrilintide combination.

What does GLP-3 RTA do?

GLP-3 RTA activates GLP-1, GIP and glucagon receptors and has been investigated in clinical trials involving obesity and metabolic conditions.

What does Cagrilintide do?

Cagrilintide is an amylin analogue investigated for its effects on satiety, appetite and body-weight regulation.

Is GLP-3 RTA + Cagrilintide the same as CagriSema?

No. CagriSema refers to a combination of cagrilintide and semaglutide. This blend contains GLP-3 RTA and cagrilintide.

Is GLP-3 RTA + Cagrilintide proven to improve weight loss?

No. The safety and effectiveness of this specific combined formulation have not been established through adequate human clinical trials.

Is the 15mg blend approved for medical use?

No. This combined research formulation is not an established approved medical treatment.

Can the two compounds be stored together?

Compatibility and stability in a single vial require formulation-specific evidence. They should not be assumed based on individual compound data.

Is this blend suitable for injection?

A labelled strength or purity test alone cannot establish sterility, safety or suitability for injection.

Is batch testing documentation available?

Contact Atlas Longevity to request available batch-specific documentation.

Is this blend available in Bali?

Contact Atlas Longevity for product information and regulatory status. Any supply is subject to applicable legal requirements.


Research Disclaimer

For laboratory research purposes only. Not for human consumption.

GLP-3 RTA and cagrilintide are investigational compounds. The combined formulation has not been established as safe or effective for human administration.

This product is not intended to diagnose, treat, cure or prevent any disease.